• News
  • SAN DIEGO
  • BioTech

Adamis completes acquisition of 3M assets, IP

Adamis Pharmaceuticals Corp. (Nasdaq: ADMP) announced Tuesday that it recently made a final payment of $7 million to fully acquire from 3M Co. (NYSE: MMM) and 3M Innovative Properties Co. certain intellectual property and assets.

Adamis said the payment was made at a closing held Dec. 27 and covers the acquisition of certain property and assets related to 3M's Taper Dry Powder Inhaler technology, under development for the treatment of asthma and chronic obstructive pulmonary disease. Adamis said it intends to utilize the assets initially to undertake efforts to develop a dry powder inhaler device for the treatment of asthma and COPD to deliver the same active ingredients as GlaxoSmithKline's Advair Diskus.

Acquired intellectual property in the transaction includes patents, patent applications and other intellectual property relating to the Taper assets.

On Aug. 1, Adamis announced it had made an initial payment to 3M of $3 million and obtained an exclusive worldwide license to the assets and intellectual property in all indications in the dry powder inhalation field through the end of 2013. The agreement provided that upon a subsequent closing payment by Adamis of an additional $7 million before Dec. 31, 2013, and satisfaction of other customary closing conditions, ownership of the assets and intellectual property would be transferred to Adamis. Adamis granted back to 3M a license to the intellectual property assets outside of the dry powder inhalation field.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Adamis Pharmaceuticals Corp.

Company Website

11455 El Camino Real
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ADMP
3.96
  0.09  
+ 2.33%
11,339,000
7.26
3.05

Adamis Pharmaceuticals Corp. Executive(s):

Dennis Carlo

  • Chief Executive Officer, President

Robert Hopkins

  • Chief Financial Officer

Related Articles

Similar Companies

NAICS - 325620 - Toilet Preparation Manufacturing
NAICS - 339112 - Surgical and Medical Instrument Manufacturing